Study Comparing Pasritamig and Docetaxel to Docetaxel Alone in Patients with Advanced Prostate Cancer

Inclusion Criteria

• Have a confirmed diagnosis of prostate cancer.
• Cancer must have spread to other parts of the body at the time of screening.
• Must be receiving ongoing hormone therapy to lower male hormone levels or have had surgery to remove the testicles, with testosterone levels at or below 50 ng/dL at screening.
• Have previously tried at least one treatment targeting androgen receptors but no more than two, and must have stopped these treatments before joining the study.
• Be in good overall health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.

Exclusion Criteria

• Have a history of prostate cancer spreading to the brain or spinal fluid.
• Have known BRCA 1/2 mutations and have not been treated with a PARP inhibitor, unless unavailable or not suitable.
• Have another active cancer that could interfere with the study.
• Have received chemotherapy for prostate cancer in any setting.
• Have been treated with therapies targeting human kallikrein 2 (KLK-2).